Alterity Therapeutics
ATHE
21 hedge funds and large institutions have $553K invested in Alterity Therapeutics in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
2,519% more call options, than puts
Call options by funds: $550K | Put options by funds: $21K
22% more capital invested
Capital invested by funds: $454K → $553K (+$99.1K)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$163K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$49.7K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$28.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.4K |
| 5 |
CAM
Columbia Asset Management
Ann Arbor,
Michigan
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$47.6K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$40.1K |
| 4 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
-$17K |
| 5 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$17K |
ATHE Hedge Fund Activity: Q2 2015 in Review
21 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2015, worth a combined $553K — up 22% from $454K a quarter earlier.
Fund positioning in ATHE was balanced in Q2 2015: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $163K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $61.5K sold.
- 21 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $553K of Alterity Therapeutics stock for Q2 2015, up 22% quarter-over-quarter.
- 5 funds opened new Alterity Therapeutics positions in Q2 2015 and 5 closed out, a net change of 0 holders.
- The largest Alterity Therapeutics buyer in Q2 2015 was Virtu KCG Holdings, an estimated $163K added.
- The largest Alterity Therapeutics seller in Q2 2015 was Susquehanna International Group, an estimated $61.5K sold.
Based on aggregated 13F filings for Q2 2015.